Want to see JANX full AI Analyst Report?
Top Page
Janux Therapeutics Inc
(NASDAQ:JANX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$19.00
▲(1.71% Upside)
Action:Reiterated
Date:08/07/26
JANX scores mid-range primarily due to a strong balance sheet (very low leverage) and improving revenue momentum, offset by substantial ongoing losses and continued negative free cash flow. Technicals are modestly supportive, while valuation metrics are constrained by negative earnings and lack of dividend data.
Positive Factors
Low leverage
Very low leverage gives Janux substantial financial flexibility while it funds clinical development and absorbs setbacks. Limited borrowing reduces interest and refinancing pressure, allowing more of its capital base to support research, partnerships, and pipeline advancement over the next several quarters.
Negative Factors
Deep operating losses
Janux remains far from breakeven, with substantial R&D and operating spending relative to its revenue base. Persistent losses reduce internally generated funding and make future progress dependent on continued financing, collaboration proceeds, or successful advancement of development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage gives Janux substantial financial flexibility while it funds clinical development and absorbs setbacks. Limited borrowing reduces interest and refinancing pressure, allowing more of its capital base to support research, partnerships, and pipeline advancement over the next several quarters.
Read all positive factors
Janux Therapeutics Inc (JANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.12B
Dividend YieldN/A
Average Volume (3M)933.51K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth5366.97%
EPS Growth8.50%
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.65
Shares Outstanding61,136,772
10 Day Avg. Volume817,486
30 Day Avg. Volume933,513
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$34.22Price Target Upside83.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$31.62M
Janux Therapeutics Inc Business Overview & Revenue Model
Company Description
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate t...
How the Company Makes Money
Janux Therapeutics primarily generates revenue through collaboration- and partnership-related payments rather than product sales, as it is a clinical-stage company. Its revenue model typically includes (1) upfront payments received when entering d...
Janux Therapeutics Inc Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.00M | 10.00M | 10.59M | 8.08M | 8.61M | 3.64M |
| Gross Profit | 24.00M | 7.97M | 8.53M | 6.13M | 7.77M | -22.60M |
| EBITDA | -100.69M | -111.60M | -66.93M | -56.34M | -62.22M | -32.56M |
| Net Income | -102.59M | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 1.01B | 1.06B | 380.41M | 364.01M | 379.82M |
| Cash, Cash Equivalents and Short-Term Investments | 970.91M | 966.57M | 1.03B | 344.03M | 327.02M | 374.96M |
| Total Debt | 20.99M | 22.14M | 23.02M | 24.54M | 25.30M | 194.00K |
| Total Liabilities | 79.67M | 50.70M | 38.73M | 36.06M | 43.27M | 13.50M |
| Stockholders Equity | 927.98M | 956.82M | 1.02B | 344.35M | 320.74M | 366.33M |
Cash Flow | ||||||
| Free Cash Flow | -41.92M | -83.28M | -44.17M | -52.42M | -49.37M | -18.46M |
| Operating Cash Flow | -41.25M | -82.23M | -43.81M | -50.58M | -42.92M | -16.98M |
| Investing Cash Flow | 7.35M | -300.98M | -258.02M | -41.19M | 58.27M | -340.96M |
| Financing Cash Flow | 9.22M | 4.95M | 713.24M | 59.55M | 500.00K | 386.52M |
Janux Therapeutics Inc Technical Analysis
Positive
18.68
Price Trends
17.32
Positive
16.09
Positive
15.08
Positive
Market Momentum
0.10
Negative
59.33
Neutral
79.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Positive. The current price of 18.68 is above the 20-day moving average (MA) of 17.01, above the 50-day MA of 17.32, and above the 200-day MA of 15.08, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 59.33 is Neutral, neither overbought nor oversold. The STOCH value of 79.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JANX.
Janux Therapeutics Inc Risk Analysis
Janux Therapeutics Inc disclosed 79 risk factors in its most recent earnings report. Janux Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Janux Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $346.39M | 2.82 | -38.12% | ― | 30.47% | ― | |
56 Neutral | $1.12B | -11.15 | -10.79% | ― | 5366.97% | 8.50% | |
56 Neutral | $599.17M | -11.71 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.51B | -163.01 | -2.35% | ― | 20.19% | ― | |
48 Neutral | $1.11B | -4.17 | -47.04% | ― | -65.40% | -164.71% | |
44 Neutral | $560.00M | -5.71 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
JANX
Janux Therapeutics Inc
18.39
-7.90
-30.05%
AGEN
Agenus
7.67
3.62
89.38%
CTMX
CytomX Therapeutics
2.57
-0.83
-24.41%
IMTX
Immatics
7.43
-2.66
-26.36%
STTK
Shattuck Labs
5.97
4.13
224.46%
IMCR
Immunocore Holdings
29.39
-2.96
-9.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.